A New Era of Continuous Health
Monitoring and Clinical Intelligence

Introducing the TempleGuard:
The discreet wearable for long-time, continuous CVD monitoring.

Our Vision

Equipping patients, caregivers and physicians with non-stop, real-time remote patient monitoring of cardiovascular disease.

Our Mission

To build a discreet monitoring device fixed on any eyeglasses frame that collects crucial information, processes it via deep learning algorithms and makes it available at the right time.

Target Market​

9.7% of men
7.6% of women

Had CVD, diabetes mellitus, or received lipid-lowering or antihypertensive treatment*.

0 M
People

Died from CVD in 2018, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and stroke**.

Market potential

Health monitoring wearables

Market trends and drivers

Costly

Costly

TREATMENT AND HOSPITALIZATION
The average hospitalization cost of of a single CVD Patient in the US is $53K. newsarchive.heart.org
Why Eyeglasses can be smart.

Why Eyeglasses can be smart.

Average distance between Eyeglasses and Smartphone is below 1 meter throughout the day.

Inconsistency

Inconsistency

POOR MEASURING
30% of CVD monitoring devices are abandoned within 6–12 months, mainly due to inconvenience in the use Ernst & Young
Non-stop day-time  Monitoring via eyeglasses

Non-stop day-time Monitoring via eyeglasses

77% of the US population in the age group above 55, constantly wear eyeglasses. statista.com

Next Gen remote CVD monitoring

Our literature review shows that the area behind the ear is the best source for PWV and PTT measurements in the human body.

From temple tip to TempleGuard

The TempleGuard is using the part of the eyeglasses that is positioned right on the ideal measuring area and is usually concealed behind the ear.

The TempleGuard Difference

User Profiling

General user profile is set up upon App installation by asking relevant question

RAW USER DATA

Stored on flash memory of TempleGuard device and transmitted to smartphone using BLE (Bluetooth Low Energy) and further from Smartphone to Cloud.

ASSUMPTIONS BASED ON DEEP LEARNING

AI Model transfers raw data into assumptions which are validated by user feedback. Feedback is used to train data models.

MONITORING AND ALERTING

Qualified predection of unfolding CVD events through cross profiling, pre-defined gold standard tresholds and AI model.

USER PROFILING

General user profile is set up upon App installation by asking relevant question

RAW USER DATA

Stored on flash memory of TempleGuard device and transmitted to smartphone using BLE (Bluetooth Low Energy) and further from Smartphone to Cloud.

 

ASSUMPTIONS BASED ON DEEP LEARNING

AI Model transfers raw data into assumptions which are validated by user feedback. Feedback is used to train data models.

MONITORING AND ALERTING
Qualified predection of unfolding CVD events through cross profiling, pre-defined gold standard tresholds and AI model.

Business Model

R&D partnership
rnd1
Collaborators

Literature Review

Pulsewave’s Co-founders

Peter Weisz, CEO and Co-Founder

MBA from LMU, Munich. Born 1970 in Munich, Germany. Founder of Fitinstructor, an online Fitness plan database and Nutritional Planning software. Founder of WM Fahne 2006. Sold more than 4 Million Car flags during the FIFA 2006 World Cup in Germany and the 2008 FIFA EURO in Austria/Switzerland. As CEO of Swiss Nahrin AG, managed the successful turnaround of the Nahrin AG daughter companies in Russia, Ukraine, Estonia and Latvia between 2009 and 2013. Invented and developed the Findy Eyeglasses tracker, the smallest and lightest tracking device in the world. 3rd Runner up, EY Switzerland – Entrepreneur of the Year, 2006

Assaf Grundman, CTO and Co-Founder

Bachelor’s degree in electrical engineering, Bar-Ilan University. Specialization in Nano Technology and Bio Engineering. Expert in deep learning and reinforcement learning. Born 1988 in Raanana, Israel. CSO of ICZ, Zurich, Switzerland from 2010 till 2015. Head of Signal processing at Integrity Diagnostics, Israel between 2016 and 2018. Led the development of the Findy Eyeglasses tracker, the smallest and lightest tracking device in the world.

Itai Pasternak, Co-Founder and MD

Dr. Pasternak studied medicine at the University of Zurich. After graduating in 2003 he wrote his thesis on liver tumors at the department of Surgey of the University Hospital in Zurich. Since 2005 he has been practicing surgery in and around Zurich. From the beginning of his clinical career he engaged in clinical research and has published articles in peer reviewed scientific journals on different subjects in surgery and hand surgery. There are more than a dozen citations of Dr. Pasternaks research. Dr. Itai Pasternak has completed fellowships in General Surgery and Hand Surgery and is an accredited General Surgeon by the Swiss Board of Medicine and an accredited Hand Surgeon by the Swiss and European Boards of Hand Surgery.

Read More

He was also a member of the Swiss Army Medical Corps where he engaged in General Practice until his release from service in 2013.

 

Since 2018 he has successfully built up the Hand Surgery Unit within the Department of Surgery of the rural tertiary referral hospital in Muri, Switzerland. In his daily work he is in close contact with specialists of all fields of medicine and actively takes part in continuous medical education and training of fellow physicians.

Collaborators and Advisors

Prof. Thomas Niederhauser - Professor for Biomedical Signal Processing and Control

Professor Niederhauser is research fellow at the Institute for Human Centered Engineering at the Bern University of Applied Sciences (BFH). After an industrial apprenticeship in Electrical Engineering, he received his diploma in Electrical and Communication Technology from the BFH in 2007 and his MSc degree in Biomedical Engineering from the University of Bern in 2009. From 2007 to 2009, he did industrial research at the Institute for Mechatronic Systems at the BFH. He then joined the ARTORG Center, Cardiovascular Engineering, where he performed research on low-power hardware and signal processing algorithms for long-term heart rhythm monitoring.

Read More

In 2014, he earned his PhD degree in Biomedical Engineering from the University of Bern. After a short research visit at the Bern University Hospital, he was appointed as junior professor (tenure track) for Biomedical Engineering at the Institute for Human Centered Engineering at the BFH in 2015. He holds undergraduate lecturers in Feedback Control at the BFH and graduate lectures in Cardiovascular Technology at the University of Bern. He recently received a certificate as quality manager in medical technology.
His main research activities comprise novel technologies for long-term recording of physiologic functions. In particular, he focuses on the design of low-power hardware and signal processing algorithms for active medical devices intended for cardiac rhythm management and neurological monitoring of preterm infants.

Jon H. Hoem - Innosuisse Head Coach

Jon has, over the last 27 years, founded and developed several medical device companies including Medistim ASA, AtriCure Europe, Miracor Medical Systems and CorFlow Therapeutics, where he served as the CEO. He has a passion for early-stage cardio-vascular companies and has detailed insights into the preclinical and clinical development processes of these companies.

Brendan Hughes - Innosuisse Innovation Mentor

Brendan Hughes holds an Electronic Engineering degree and an MBA from IMD Lausanne. His experience covers hardware and software design, marketing and sales of high-tech and industrial products and services at SMEs and multinationals. He has held managerial positions with P&L responsibility in sectors including telecoms, the electrical industry, life sciences and the mechanical engineering industry, with sales in Switzerland and abroad

Prof. Stan Finkelstein

Stan Finkelstein, MD is a senior research scientist. He also serves as an associate professor of medicine at Harvard Medical School and a faculty member of the Division of Clinical Informatics at Beth Israel Deaconess Medical Center. He received his MS and BS degrees in chemical engineering from MIT in 1971, and an MD from Harvard Medical School in 1975.

Read More

Since 1975, he has worked actively in the field of medical technology assessment and transfer at MIT. He conducts research and teaches classes in the development and evaluation of medical practice and technology and in health economics and policy, both at MIT and Harvard Medical School.

An active consultant to U.S. and international pharmaceutical, biotechnology, and medical device firms, as well as to health services organizations and government agencies; Dr. Finkelstein is an expert in outcomes research. His areas of specialization extend to the business-government interface related to medical technology, especially product development, clinical research design and third-party reimbursement. Dr. Finkelstein is author, editor, or contributor to several books and numerous articles on these subjects.

Contact Us